Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma

Pigment Cell and Melanoma Research

Volumn 27, Issue 3, 2014, Pages 465-478

  Rebecca, Vito W ^a   Massaro, Renato R ^b   Fedorenko, Inna V ^a   Sondak, Vernon K ^a   Anderson, Alexander R A ^a   Kim, Eunjung ^a   Amaravadi, Ravi K ^c   Maria Engler, Silvya S ^b   Messina, Jane L ^a,d   Gibney, Geoffrey T ^a   Kudchadkar, Ragini R ^a   Smalley, Keiran S M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

AKT; Apoptosis; Autophagy; BRAF; Chemotherapy; Melanoma

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; B RAF KINASE; BAFILOMYCIN; CARBOPLATIN; PACLITAXEL; PROTEIN KINASE B; REACTIVE OXYGEN METABOLITE; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; BRAF PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; PROTEIN KINASE INHIBITOR; TUMOR PROTEIN;

AGED; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; BRAIN METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CASE REPORT; CELL DEATH; CELL SURVIVAL; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; ELECTRON MICROSCOPY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IN VITRO STUDY; LIVER METASTASIS; LONG TERM CARE; LYMPH NODE METASTASIS; MALE; MELANOMA; MELANOMA CELL; MTT ASSAY; PHASE 1 CLINICAL TRIAL (TOPIC); PYROSEQUENCING; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; CELL CLONE; DRUG EFFECTS; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SCREENING; ENZYMOLOGY; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTICELLULAR SPHEROID; PATHOLOGY; SKIN NEOPLASMS;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AUTOPHAGY; CARBOPLATIN; CLONE CELLS; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FEMALE; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; MALE; MELANOMA; MOLECULAR TARGETED THERAPY; NEOPLASM PROTEINS; PACLITAXEL; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; REACTIVE OXYGEN SPECIES; SKIN NEOPLASMS; SPHEROIDS, CELLULAR; TUMOR STEM CELL ASSAY;

EID: 84898872462     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12227     Document Type: Article

References (53)

1. Algazy, K.M., Schuchter, L., Demichele, A.M., David, V.J., Torigian, D.A., Chang, C.Y., Redlinger, M., Davis, L.E., O'dwyer, P.J., and Amaravadi, R. (2011). Combined mTOR and autophagy inhibition: Phase I trial of temsirolimus and hydroxychloroquine in patients with advanced solid tumors. AACR Annual Meeting Abstracts, 4500.
2. Ascierto, P.A., Schadendorf, D., Berking, C. et al. (2013). MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol. 14, 249-256.
3. Baerga, R., Zhang, Y., Chen, P.H., Goldman, S., and Jin, S. (2009). Targeted deletion of autophagy-related 5 (atg5) impairs adipogenesis in a cellular model and in mice. Autophagy 5, 1118-1130.
4. Bedogni, B., O'neill, M.S., Welford, S.M., Bouley, D.M., Giaccia, A.J., Denko, N.C., and Powell, M.B. (2004). Topical treatment with inhibitors of the phosphatidylinositol 3′-kinase/Akt and Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathways reduces melanoma development in severe combined immunodeficient mice. Cancer Res. 64, 2552-2560.
5. Berger, M.F., Hodis, E., Heffernan, T.P. et al. (2012). Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485, 502-506.
6. Boisvert-Adamo, K., and Aplin, A.E. (2008). Mutant B-RAF mediates resistance to anoikis via Bad and Bim. Oncogene 27, 3301-3312.
7. Cartlidge, R.A., Thomas, G.R., Cagnol, S., Jong, K.A., Molton, S.A., Finch, A.J., and Mcmahon, M. (2008). Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival. Pigment Cell Melanoma Res. 21, 534-544.
8. Chapman, P.B., Hauschild, A., Robert, C. et al. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N. Engl. J. Med. 364, 2507-2516.
9. Cheng, Y., Zhang, Y., Zhang, L. et al. (2012). MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis. Mol. Cancer Ther. 11, 154-164.
10. Dankort, D., Curley, D.P., Cartlidge, R.A., Nelson, B., Karnezis, A.N., Damsky, W.E. Jr, You, M.J., Depinho, R.A., Mcmahon, M., and Bosenberg, M. (2009). Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41, 544-552.
11. Datta, S.R., Dudek, H., Tao, X., Masters, S., Fu, H., Gotoh, Y., and Greenberg, M.E. (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91, 231-241.
12. Davies, M.A., Stemke-Hale, K., Tellez, C., Calderone, T.L., Deng, W., Prieto, V.G., Lazar, A.J., Gershenwald, J.E., and Mills, G.B. (2008). A novel AKT3 mutation in melanoma tumours and cell lines. Br. J. Cancer 99, 1265-1268.
13. Degtyarev, M., De Maziere, A., Orr, C. et al. (2008). Akt inhibition promotes autophagy and sensitizes PTEN-null tumors to lysosomotropic agents. J. Cell Biol. 183, 101-116.
14. Devitt, B., Liu, W., Salemi, R., Wolfe, R., Kelly, J., Tzen, C.Y., Dobrovic, A., and Mcarthur, G. (2011). Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma. Pigment Cell Melanoma Res. 24, 666-672.
15. Dhawan, P., Singh, A.B., Ellis, D.L., and Richmond, A. (2002). Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. Cancer Res. 62, 7335-7342.
16. Diehl, J.A., Cheng, M., Roussel, M.F., and Sherr, C.J. (1998). Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev. 12, 3499-3511.
17. Fedorenko, I.V., Paraiso, K.H., and Smalley, K.S. (2011). Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma. Biochem. Pharmacol. 82, 201-209.
18. Fedorenko, I.V., Gibney, G.T., and Smalley, K.S. (2013). NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene 32, 3009-3018.
19. Flaherty, K.T., Puzanov, I., Kim, K.B. et al. (2010). Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809-819.
20. Flaherty, K.T., Robert, C., Hersey, P. et al. (2012). Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med. 367, 107-114.
21. Frame, S., and Cohen, P. (2001). GSK3 takes centre stage more than 20 years after its discovery. Biochem. J. 359, 1-16.
22. Hauschild, A., Grob, J.J., Demidov, L.V. et al. (2012). Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 380, 358-365.
23. Hirai, H., Sootome, H., Nakatsuru, Y. et al. (2010). MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol. Cancer Ther. 9, 1956-1967.
24. Hodis, E., Watson, I.R., Kryukov, G.V. et al. (2012). A landscape of driver mutations in melanoma. Cell 150, 251-263.
25. Infante, J.R., Falchook, G.S., Lawrence, D.A. et al. (2011). Phase I/II study of the oral MEK1/2 inhibitor GSK1120212 dosed in combination with the oral BRAF inhibitor GSK2118436. J. Clin. Oncol. 29, CRA8503.
26. Jaiswal, B.S., Janakiraman, V., Kljavin, N.M., Eastham-Anderson, J., Cupp, J.E., Liang, Y., Davis, D.P., Hoeflich, K.P., and Seshagiri, S. (2009). Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS ONE 4, e5717.
27. Kim, K., Amavaradi, R.K., Flaherty, K., Chapman, P.B., Ribas, A., Mcarthur, G., Sosman, J., Nolop, K., and Puzanov, I. (2012). Significant long-term survival benefit demonstrated with vemurafenib in ongoing phase I study. Pigment Cell Melanoma Res. 25, 866.
28. Krauthammer, M., Kong, Y., Ha, B.H. et al. (2012). Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat. Genet. 44, 1006-1014.
29. Liu, Z.J., Xiao, M., Balint, K., Smalley, K.S., Brafford, P., Qiu, R., Pinnix, C.C., Li, X., and Herlyn, M. (2006). Notch1 signaling promotes primary melanoma progression by activating mitogen-activated protein kinase/phosphatidylinositol 3-kinase-Akt pathways and up-regulating N-cadherin expression. Cancer Res. 66, 4182-4190.
30. Lum, J.J., Bauer, D.E., Kong, M., Harris, M.H., Li, C., Lindsten, T., and Thompson, C.B. (2005). Growth factor regulation of autophagy and cell survival in the absence of apoptosis. Cell 120, 237-248.
31. Ma, X.H., Piao, S., Wang, D., Mcafee, Q.W., Nathanson, K.L., Lum, J.J., Li, L.Z., and Amaravadi, R.K. (2011). Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma. Clin. Cancer Res. 17, 3478-3489.
32. Madhunapantula, S.V., and Robertson, G.P. (2009). The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res. 22, 400-419.
33. Maertens, O., Johnson, B., Hollstein, P. et al. (2013). Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov. 3, 338-349.
34. Mathew, R., Karantza-Wadsworth, V., and White, E. (2007). Role of autophagy in cancer. Nat. Rev. Cancer 7, 961-967.
35. Paraiso, K.H., Fedorenko, I.V., Cantini, L.P., Munko, A.C., Hall, M., Sondak, V.K., Messina, J.L., Flaherty, K.T., and Smalley, K.S. (2010). Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer 102, 1724-1730.
36. Paraiso, K.H., Xiang, Y., Rebecca, V.W. et al. (2011). PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 71, 2750-2760.
37. Posch, C., Moslehi, H., Feeney, L. et al. (2013). Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc. Natl Acad. Sci. USA 110, 4015-4020.
38. Qu, X., Yu, J., Bhagat, G. et al. (2003). Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. J. Clin. Investig. 112, 1809-1820.
39. Rabinowitz, J.D., and White, E. (2010). Autophagy and metabolism. Science 330, 1344-1348.
40. Ravikumar, B., Vacher, C., Berger, Z. et al. (2004). Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 36, 585-595.
41. Smalley, K.S., and Sondak, V.K. (2010). Melanoma-an unlikely poster child for personalized cancer therapy. N. Engl. J. Med. 363, 876-878.
42. Smalley, K.S., Haass, N.K., Brafford, P.A., Lioni, M., Flaherty, K.T., and Herlyn, M. (2006). Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol. Cancer Ther. 5, 1136-1144.
43. Smalley, K.S., Lioni, M., Noma, K., Haass, N.K., and Herlyn, M. (2008). In vitro three-dimensional tumor microenvironment models for anticancer drug discovery. Expert Opin. Drug Discov. 3, 1-10.
44. Sotelo, J., Briceno, E., and Lopez-Gonzalez, M.A. (2006). Adding chloroquine to conventional treatment for glioblastoma multiforme: a randomized, double-blind, placebo-controlled trial. Ann. Intern. Med. 144, 337-343.
45. Stahl, J.M., Sharma, A., Cheung, M., Zimmerman, M., Cheng, J.Q., Bosenberg, M.W., Kester, M., Sandirasegarane, L., and Robertson, G.P. (2004). Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64, 7002-7010.
46. Tormo, D., Checinska, A., Alonso-Curbelo, D. et al. (2009). Targeted activation of innate immunity for therapeutic induction of autophagy and apoptosis in melanoma cells. Cancer Cell 16, 103-114.
47. Tsao, H., Goel, V., Wu, H., Yang, G., and Haluska, F.G. (2004). Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol. 122, 337-341.
48. Vredeveld, L.C., Possik, P.A., Smit, M.A. et al. (2012). Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis. Gene Dev. 26, 1055-1069.
49. Xi, G., Hu, X., Wu, B., Jiang, H., Young, C.Y., Pang, Y., and Yuan, H. (2011). Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells. Cancer Lett. 307, 141-148.
50. Xie, X., White, E.P., and Mehnert, J.M. (2013). Coordinate autophagy and mTOR pathway inhibition enhances cell death in melanoma. PLoS ONE 8, e55096.
51. Xu, Y., Yu, H., Qin, H., Kang, J., Yu, C., Zhong, J., Su, J., Li, H., and Sun, L. (2012). Inhibition of autophagy enhances cisplatin cytotoxicity through endoplasmic reticulum stress in human cervical cancer cells. Cancer Lett. 314, 232-243.
52. Yazbeck, V.Y., Buglio, D., Georgakis, G.V., Li, Y., Iwado, E., Romaguera, J.E., Kondo, S., and Younes, A. (2008). Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma. Exp. Hematol. 36, 443-450.
53. Yue, Z., Jin, S., Yang, C., Levine, A.J., and Heintz, N. (2003). Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor. Proc. Natl Acad. Sci. USA 100, 15077-15082.